{
    "organizations": [],
    "uuid": "23b7a84f29196fc4757d58a790ef6fc22015e11f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ceapro-inc-provides-corporate-upda/brief-ceapro-inc-provides-corporate-update-idUSASC09WTB",
    "ord_in_thread": 0,
    "title": "BRIEF-Ceapro Inc. Provides Corporate Update",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 23, 2018 / 1:15 PM / Updated 23 minutes ago BRIEF-Ceapro Inc. Provides Corporate Update Reuters Staff \nApril 23 (Reuters) - Ceapro Inc: * CEAPRO INC. PROVIDES CORPORATE UPDATE \n* CEAPRO INC - DATA EXPECTED FROM BIOAVAILABILITY STUDY OF COQ10-BETA GLUCAN AND RESULTS OF AVENANTHRAMIDES IN EXERCISE-INDUCED INFLAMMATION IN Q2 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-04-23T21:15:00.000+03:00",
    "crawled": "2018-04-23T16:30:21.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "provides",
        "corporate",
        "update",
        "reuters",
        "staff",
        "april",
        "reuters",
        "ceapro",
        "inc",
        "ceapro",
        "provides",
        "corporate",
        "update",
        "ceapro",
        "inc",
        "data",
        "expected",
        "bioavailability",
        "study",
        "glucan",
        "result",
        "avenanthramides",
        "inflammation",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}